The FDA has granted a priority review to a new drug application for talazoparib for the treatment of patients with germline mutation–positive, HER2-negative locally advanced or metastatic breast cancer.
Original Article: FDA Grants Talazoparib Priority Review for BRCA+ Breast Cancer